Payment overview · 2025
General Payments
$342.21
19 reported records · 5 companies
Healthcare provider profile · identity verified
Dalen Lee Johnson, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · EAST CARBON, UT · NPI 1922318450
Verified facts
What the public records show
CMS Open Payments records show Dalen Lee Johnson, APRN received $342.21 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 48.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $164.51 | 48.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.24 | 28.1% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.00 | 14.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.60 | 4.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.86 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $342.21 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $164.51 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $78.17 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $30.03 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 61 |
| Omeprazole | Omeprazole | 216 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 191 | 48 |
| Gabapentin | Gabapentin | 166 | 26 |
| Celecoxib | Celecoxib | 151 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 36 |
| Tramadol Hcl | Tramadol Hcl | 138 | 27 |
| Lisinopril | Lisinopril | 126 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 23 |
| Ozempic | Semaglutide | 104 | 15 |
| Jardiance | Empagliflozin | 100 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 15 |
| Simvastatin | Simvastatin | 86 | 19 |
| Potassium Chloride | Potassium Chloride | 84 | 26 |
| Eliquis | Apixaban | 83 | 14 |
| Furosemide | Furosemide | 77 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 27 |
| Aripiprazole | Aripiprazole | 73 | 12 |
| Mounjaro | Tirzepatide | 73 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 22 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Pregabalin | Pregabalin | 66 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 23 |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Metformin Hcl | Metformin Hcl | 60 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 57 | 17 |
| Losartan Potassium | Losartan Potassium | 56 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 53 | 13 |
| Allopurinol | Allopurinol | 52 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 30 |
| Meloxicam | Meloxicam | 50 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Alprazolam | Alprazolam | 48 | 13 |
| Famotidine | Famotidine | 47 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Lorazepam | Lorazepam | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 13 |
| Prednisone | Prednisone | 43 | 31 |
| Azithromycin | Azithromycin | 42 | 32 |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 15 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 30 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 29 |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 13 |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 13 |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Fentanyl | Fentanyl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342.21 · 19 records | ABBVIE INC. | AIRSUPRA, BREZTRI, NURTEC ODT, REXULTI, Sunosi, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error